See more : Xtant Medical Holdings, Inc. (XTNT) Income Statement Analysis – Financial Results
Complete financial analysis of Aileron Therapeutics, Inc. (ALRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aileron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Limitless X Holdings Inc. (VYBE) Income Statement Analysis – Financial Results
- G&P Acquisition Corp. (GAPA-UN) Income Statement Analysis – Financial Results
- FVCBankcorp, Inc. (FVCB) Income Statement Analysis – Financial Results
- The Indian Card Clothing Company Limited (INDIANCARD.NS) Income Statement Analysis – Financial Results
- AuSom Enterprise Limited (AUSOMENT.NS) Income Statement Analysis – Financial Results
Aileron Therapeutics, Inc. (ALRN)
About Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.35M |
| Cost of Revenue | 119.00K | 169.00K | 121.00K | 163.00K | 155.00K | 218.00K | 95.00K | 232.00K | 325.00K | 9.33M | 12.23M |
| Gross Profit | -119.00K | -169.00K | -121.00K | -163.00K | -155.00K | -218.00K | -95.00K | -232.00K | -325.00K | -9.33M | 10.12M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45.29% |
| Research & Development | 3.99M | 17.97M | 17.01M | 11.17M | 17.66M | 18.45M | 14.24M | 10.28M | 7.83M | 9.33M | 12.23M |
| General & Administrative | 11.36M | 9.68M | 9.60M | 9.33M | 12.29M | 13.45M | 8.77M | 7.89M | 5.06M | 6.70M | 6.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.36M | 9.68M | 9.60M | 9.33M | 12.29M | 13.45M | 8.77M | 7.89M | 5.06M | 6.70M | 6.84M |
| Other Expenses | 928.00K | 318.00K | 441.00K | -800.00K | 0.00 | 0.00 | 0.00 | -18.17M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 16.28M | 27.65M | 26.61M | 20.50M | 29.96M | 31.90M | 23.01M | 18.17M | 12.89M | 6.70M | 6.84M |
| Cost & Expenses | 16.28M | 27.65M | 26.61M | 20.50M | 29.96M | 31.90M | 23.01M | 18.17M | 12.89M | 16.03M | 19.07M |
| Interest Income | 0.00 | 0.00 | 0.00 | 587.00K | 355.00K | 404.00K | 46.00K | 13.00K | 10.00K | 6.00K | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 119.00K | 169.00K | 121.00K | 163.00K | 155.00K | 218.00K | 95.00K | 232.00K | 325.00K | 585.00K | 774.00K |
| EBITDA | -15.61M | -27.48M | -26.48M | -20.33M | -29.80M | -31.33M | -23.01M | -17.94M | -12.57M | -15.44M | 4.06M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 18.16% |
| Operating Income | -16.28M | -27.65M | -26.61M | -20.50M | -29.96M | -31.90M | -23.01M | -18.17M | -12.89M | -16.03M | 3.28M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.69% |
| Total Other Income/Expenses | 544.00K | 318.00K | 441.00K | -661.00K | 587.00K | 355.00K | 404.00K | 46.00K | 13.00K | 10.00K | 6.00K |
| Income Before Tax | -15.73M | -27.33M | -26.21M | -21.16M | -29.37M | -31.55M | -22.60M | -18.12M | -12.88M | -16.02M | 3.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.72% |
| Income Tax Expense | 0.00 | -318.00K | -441.00K | 661.00K | -587.00K | 355.00K | 34.00K | 0.00 | 0.00 | 43.00K | 3.10M |
| Net Income | -15.73M | -27.01M | -25.76M | -21.82M | -28.78M | -31.55M | -22.60M | -18.12M | -12.88M | -16.07M | 194.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.87% |
| EPS | -3.42 | -5.95 | -5.80 | -12.52 | -23.46 | -42.81 | -60.74 | -33.21 | -23.60 | -845.63 | 10.21 |
| EPS Diluted | -3.42 | -5.95 | -5.80 | -12.52 | -23.46 | -42.81 | -60.74 | -33.21 | -23.60 | -844.96 | 10.85 |
| Weighted Avg Shares Out | 4.60M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 545.72K | 545.72K | 19.00K | 19.00K |
| Weighted Avg Shares Out (Dil) | 4.60M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 545.72K | 545.72K | 19.02K | 17.89K |
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021
Aileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings
Aileron Therapeutics to be Added to the Russell Microcap® Index
Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities
Aileron Therapeutics: Solving Chemotherapy's Toxicity
Aileron Therapeutics: Low Cash Balance, Early Stage, But Scientific Premise Is Interesting
7 Penny Stocks That Actually Have Buy Ratings
Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners
Source: https://incomestatements.info
Category: Stock Reports